PREVALENCE THRESHOLD THAT SHOULD BE APPLIED IN SCHISTOSOMIASIS MASS DRUG ADMINISTRATION PRGROGRAMMES: SYSTEMATIC REVIEW AND META-ANALYSIS

Anthony Danso-Appiah^{1*}, Amadou Djirmay Garba², Massimiliano Orso³, Kwadwo Owusu Akuffo⁴, Fiona M. Fleming⁵, Guo Jiangang², Pauline Mwinzi⁶, Daniel G. Colley⁷, M. Hassan Murad⁸, Paul Hagan⁹, Paolo Eusebi³

¹ University of Ghana Centre for Evidence Synthesis and Policy (UGCESP), School of Public Health, P. O. Box LG13, Legon, Accra, Ghana

²Schistosomiasis Control Programme, WHO Department of Control of Neglected Tropical Diseases, Geneva, Switzerland

³Health Planning Service, Regional Health Authority of Umbria, Italy

⁴Department of Optometry and Visual Science, College of Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

⁵Schistosomiasis Control Initiative Foundation, Edinburgh House, 170 Kennington Lane, Lambeth, London SE11 5DP, UK

⁶Schisto and STH, ESPEN, AFRO, Brazzaville, Congo Brazzaville

⁷ Center for Tropical and Emerging Global Diseases, University of Georgia, Room 330B -Coverdell Center, 500 D.W. Brooks Drive -30602 - Athens Georgia, United States

⁸ The Kern Center for the Science of Healthcare Delivery, Mayo Clinic, Rochester, Minnesota, USA

⁹Robert Gordon University, Garthdee House, Garthdee Road, Aberdeen, AB10 7QB, UK.

* Correspondance : Anthony Danso-Appiah, University of Ghana Centre for Evidence Synthesis and Policy, Legon, Accra, Ghana. Email: <u>adanso-appiah@ug.edu.gh; tdappiah@yahoo.co.uk</u>

ABSTRACT

Background

WHO-recommended prevalence thresholds for deciding schistosomiasis mass drug administration (MDA) are based on anecdotal evidence and unclear.

Objectives

This systematic review and meta-analysis commissioned by the WHO, as part of its new schistosomiasis evidence-based guideline development, was to generate a single and 'global' prevalence threshold that should be applied in MDA programmes.

Methods

We searched several databases from 1979 to 31st March 2021 without language restriction. Two reviewers selected studies, extracted data and assessed the risk of bias using relevant risk of bias tools and resolved disagreements through discussion. The review followed the PRISMA guidelines. Data were analysed and presented as prevalence reduction (PR) and relative risk (RR) for dichotomous outcomes or mean difference for continuous outcomes with their 95% confidence intervals (CIs). Meta-regression of observations on prevalence rates and intensity of infection of MDA programmes and sensitivity analyses to assess the robustness of the results to the risk of bias components were performed. Evidence on benefits, harms, values, preferences, compliance, acceptability, equity and feasibility were also assessed. The overall level of evidence was graded using GRADE.

Results

Out of 1,232 studies retrieved, 38 studies met our inclusion criteria and 34 studies were included in the meta-analysis. No direct relation was observed between prevalence and intensity of infection. Praziguantel reduced prevalence of S. haematobium in school age children (SAC) at 12 months (RR 0.38, 95% CI 0.28 to 0.52; 8 studies, n=37,868); at 24 months (RR 0.30; 95% CI 0.30 to 0.52; 7 studies; n=37107); at 36 months (RR 0.39, 95% CI 0.21 to 0.71; 5 studies, n=28,146). There was no significant reduction in prevalence at 48 months (2 studies, n=10,954). For S. mansoni, there were reductions in prevalence at 12 months (RR 0.56, 95% CI 0.46 to 0.69; 14 studies, n=86,073); 24 months (RR 0.46; 95% CI 0.32 to 0.66; 14 studies; n=83,721);36 months (RR 0.44, 95% CI 0.33 to 0.58; 7 studies, n=70,933) and at 48 months (RR 0.25, 95% CI 0.11 to 0.59; 5 studies; n=27,483). Further analyses were performed from a series of created prevalence thresholds of 5%, 10%, 15%, 20%, 30% and \geq 40% which showed differences in effect of MDA when each of the thresholds was applied. For annual MDA of school age children (SAC), school-based treatment (SBT) appears to perform better than community-wide treatment (CWT) in terms of prevalence reduction. For the different schistosome species, the model suggests, using the same prevalence threshold, it will take shorter time to reach elimination for S. haematobium than S. mansoni; annual MDA using SBT approach for S. haematobium will require about 10 years to achieve elimination whereas it will take over 10 years to around 15 years to achieve elimination for S. mansoni.

Conclusion

The evidence presented in this systematic review suggests that 10% prevalence should be used as the global prevalence threshold for implementing MDA in endemic countries.

BACKGROUND

The ultimate goal of schistosomiasis control is to prevent new infection or transmission by interrupting the parasite's lifecycle. This has been difficult to achieve, therefore, WHO guidelines have changed several times over the years from selective treatment (i.e. screening entire populations and treating positive cases), morbidity control to focus on symptomatic individuals or those with heavy worm loads and likely to suffer infection-related complications and passive case finding (push for hospital attendance by individuals with schistosomiasis-related symptoms) to Preventive chemotherapy (PC) adopted in the new millennium at the World Assembly (WHA54.19) in 2001 (WHO 1985; WHO 1993; WHO 1998; WHO 2002; WHO 2006; WHO 2012a; WHO 2012).

Within the PC concept backed by resolution WHA54.19, endemic countries were urged to embark on mass drug administration (MDA) with Praziquantel (PZQ) at a single 40 mg/kg oral dose to treat at least 75% of school-aged children at risk of the infection by 2010 (WHO 2002). WHO experts met and developed operational guidelines from Resolution WHA54.19 with emphasis on morbidity control, using defined thresholds of prevalence of infection as criteria for classifying at-risk populations, and selecting appropriate intervals of mass MDA (WHO 2002). Schools-based MDA was identified as most cost-effective. Since then, hundreds of millions of school-going children living in endemic countries have received multiple treatment with PZQ. The governments of endemic countries and international non-governmental organizations including the Schistosomiasis Control Initiative (SCI), the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE), both funded by the Bill and Melinda Gates Foundation, the United States Agency for International Development (USAID) the British Department for International Development (DFID and the Global Network for neglected tropical diseases have been key in delivering MDA (Fenwick A *et al.* 2009; Hotez 2009, 2011; Linehan *et al.* 2011; King et al. 2020).

In 2006, the operational details of PC were revised (WHO 2006) to expand the target population for MDA to include adults and special risk groups, for example, occupationally exposed individuals in high-risk areas where prevalence of infection in school-age children reaches 50%. In 2012, following the release of the WHO Schistosomiasis Progress Report that reviewed the global progress towards control and elimination from 2001 to 2011 and set the agenda to guide control from 2012-2020 (WHO 2012a). The new goals (intensity-based not aligned to the prevalence-based thresholds) aimed to control morbidity and eliminate schistosomiasis as a public health problem using appropriate diagnostic criteria. It also specified that tools needed for routine testing should be sensitive and easy to use, should be able to demonstrate presence of the parasite or marker of current infection, and should easily be adapted for use in peripheral health facilities with minimum cost and resource capacity. The WHO also urged member states to increase control effort towards elimination (WHO 2012a). At the same time the NTD road map and the London Declaration of NTD encouraged partners to pledge commitment towards reaching up to 100% of school-aged children living in endemic regions by 2020, and to eliminate the disease in some regions (WHO 2012b; Uniting to Combat NTDs 2012). PZQ donation was to exceed 250 million tablets per year and Countries and Programme Managers were encouraged to deliver the medicine to all at risk populations at frequencies determined by prevalence of infection.

Resolution WHA65.21 called WHO to develop guidelines for countries to embark on elimination programs and provide tools to document progress (WHO 2012). It also requested WHO to develop procedures to evaluate the interruption of transmission and to certify that transmission of

schistosomiasis has been eliminated. Further goals and targets of the Strategic Plan recommended appropriate diagnostic approaches and tools for mapping control programmes and to verify interruption of transmission. Appropriate tools are to be selected at each stage of progress towards elimination of the disease. The test should be sensitive, easy to use in the field and be able to categorize communities according to risk profiles, taking into account likely compliance in providing specimens. Ideally, in Africa settings, the test should be able to differentiate schistosome species since most areas are co-endemic and show mixed infections in individuals.

Given that the scaling up of schistosomiasis control through PC has significantly brought down prevalence and intensity of infection in most endemic settings to levels such that routinely used diagnostic tests are no longer sensitive to detect the infection or monitor progress of control, CCA test was endorsed as representing an effective tool for the detection, monitoring and evaluation of *S. mansoni* control programmes (WHO Strategic Meeting in Geneva). The endorsement followed evidence generated from WHO-commissioned systematic review and meta-analysis that assessed the comparative accuracy of Point-of-care Circulating Cathodic Antigen (POC-CCA) and existing tools (Danso-Appiah et al. 2016; Barenbold et al. 2018).

The current thresholds for MDA with PZQ is that, if baseline prevalence among school-age children is $\geq 50\%$ by parasitological methods (intestinal and urogenital schistosomiasis) or $\geq =$ 30% if based on questionnaires for history of haematuria or $\geq 60\%$ by CCA in S. mansoni endemic areas, all school-aged children (enrolled and not enrolled) should be treated once a year. Adults considered to be at risk (from special groups to entire communities living in endemic areas) should also be treated. Additional interventions should include water, improved sanitation, hygiene education (WASH) and snail control. For baseline prevalence among school-aged children >=10% but <50\% by parasitological methods (intestinal and urogenital schistosomiasis) or <30% by questionnaire for history of haematuria or >=15% but <60% by CCA in S. mansoni endemic areas, all school-aged children (enrolled and not enrolled) should be treated once every 2 years, at least 50% of this age group should be treated each year). Adults considered to be at risk should be treated, and additional interventions such as provision of wholesome water, sanitation and hygiene education (WASH) and snail control should be combined with MDA. If prevalence is <10% by parasitological methods (intestinal and urogenital schistosomiasis) or <15% by CCA in S. mansoni endemic areas, all school-aged children (enrolled and not enrolled) should be treated twice during their primary school age, at least 33% of this age group each year. Water, sanitation and hygiene education (WASH) and snail control should complement control effort.

Until now the WHO guidelines for guiding the threshold at which MDA would be required have been based on anecdotal evidence and consensus rather than systematically synthesized evidence. This review was commissioned by the WHO to determine a global prevalence threshold that should be used to implement MDA with maximum benefit in high, moderate and low schistosomiasis endemicity settings.

REVIEW METHODS

Criteria for considering studies for this review

Types of studies

Published and unpublished studies, comparative and non-comparative, involving MDA of PZQ alone or in combination with other medicines employed in the PC strategy or commonly used in PC settings, that evaluated benefits for any of the schistosomiasis species (*S. mansoni, S.*

japonicum, S. intercalatum, S. mekongi or *S. haematobium*), were eligible for inclusion. Selective treatment studies, non-human studies and reviews were excluded.

Participants

Whole population or subgroups (preschool-aged children, school-aged children, adolescents and adults including pregnant and lactating women) infected with any human schistosome species or non-infected persons living in endemic areas who received PZQ (any brand) at a single dosing schedule (40, 50, 60, 70, or 80 mg/kg) during MDA were eligible for inclusion.

Intervention

Praziquantel at a single oral dose of 40, 50, 60, 70 and \geq 80 mg/kg or in combination with Albendazole, Mebendazole, Pyrantel pamoate or Levamisole (for soil-transmitted helminthiasis), or Albendazole plus either Ivermectin or Diethylcarbamazine [DEC] (for Lymphatic filariasis), Artemisinin-based combination therapies (ACTs) for malaria, or Azithromycin (Zithromax) for trachoma.

Control

Praziquantel at 40 mg/kg or no treatment.

Outcomes

Primary

- Prevalence of infection or percent reduction at 1, 3, 6, 12 or 24 months.
- Intensity of infection or percent reduction of egg count at 1, 3, 6, 12 and 24 months. Intensity of infection was classified as light (100 epgs), moderate (100–399 epgs) and heavy (≥399 epgs) for Kato–Katz, respectively and light (< 50) heavy (≥ 50) eggs per 10ml of urine.

Secondary

- Transmission of infection or percent reduction in transmission at 1, 3, 6, 12 or 24 months.
- Compliance, acceptability, preferences, equity and feasibility of intervention by the population.

Adverse events

- Serious adverse event (defined as any event that required hospitalization or prolongation of existing inpatients hospitalization, life threatening, presented with significant disability/ incapacity or led to congenital anomalies or birth defects).
- Non-serious event (defined as mild to moderate and/or transient events)

Search strategy for identification of studies

We identified relevant studies regardless publication status (published, unpublished, in press, and ongoing). We searched Pubmed and LILACS from 1979 to 31st March 2021 without language restriction. We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2021), mRCT, Hinari, Africa Journals Online and Google Scholar. Experts in the field of schistosomiasis were contacted for additional or unpublished data and the reference lists of articles reviewed. The following search terms were used: schistosomiasis) OR schistosoma) OR schistosome) OR "schistosoma mansoni") OR "schistosoma haematobium") OR "schistosoma hematobium") OR "schistosoma japonicum") OR "schistosoma mekongi") OR "schistosoma intercalatum") AND praziquantel) OR biltricide)

OR distocide) OR pharmamed) OR Bilharzid) OR Prazitel) AND "preventive chemotherapy") OR "mass treatment") OR "mass drug administration") OR MDA) OR "blanket treatment") AND "endemic setting") OR "endemic community") OR "endemic country").

Study selection

One reviewer screened the results of the search output to identify studies meeting the prespecified inclusion criteria using a pre-tested study selection form. Full study reports of potentially relevant studies were obtained and checked against the predefined inclusion criteria, which were verified independently by the lead reviewer. Any discrepancies were resolved through discussion between the reviewers.

Data extraction and management

Two reviewers extracted data using pre-tested data extraction form. Data extracted included study characteristics such as the country and year in which the study was conducted, the study design type as well as epidemiological and demographic characteristics – e.g. baseline endemicity, target population or subgroup that received MDA, age and number of participants involved in the MDA. We also extracted post MDA outcome data such as prevalence, egg count reduction, compliance and acceptability, equity and feasibility of treatment. We contacted some authors to see if they could clarify or supplement the results or provide raw data that we could use. If two or more communities were involved in a study, data were extracted for each community – with a link to the parent study. However, where it is not possible to separate the data by country or communities in which the study was conducted were shown. Any discrepancies were resolved through discussion between the reviewers.

Assessment of risk of bias in the included studies

One reviewer assessed the risk of bias in each of the included trials using risk of bias tool for Randomized Controlled Trials (RCTs) (Higgins et al. 2011) and verified independently by another reviewer. Where information in the trial report was unclear, we contacted the trial authors for clarification. We assessed the risk of bias for six domains: sequence generation, allocation concealment, blinding (investigators, outcome assessors and participants), incomplete outcome data, selective outcome reporting and other sources of bias. For each domain, we made a judgment of 'low risk' of bias, 'high risk' of bias or 'unclear' risk of bias. ROBINS-I (Risk Of Bias In Non-randomised Studies- of Interventions), was used to evaluate risk of bias in estimates of benefit of interventions from studies that did not use randomization to allocate individuals or clusters of individuals to comparison groups (Sterne et al. 2016). Seven domains through which bias might be introduced into non-randomized studies of intervention (NRSI) were considered. The first two domains, covering confounding and selection of participants into the study, addressed issues before the start of the interventions. The third domain addressed classification of the interventions themselves. The other four domains addressed issues after the start of interventions: biases due to deviations from intended interventions, missing data, measurement of outcomes, and selection of the reported result. The STROBE checklist was used to examine the reporting of observational comparative studies (Von Elm et al. 2007) and PRISMA for systematic review and meta-analysis (Moher et al. 2009). Risk of bias and quality results have been presented in tables. The Risk of Bias Tool for Prevalence Studies (Hoy et al. 2012) was used to assess the methodological quality and risk of bias for each prevalence study.

Data synthesis

Prevalence and absolute rate s of events were calculated from all studies and relative risks from comparative trials. Data were analysed and presented as prevalence ratios with their 95% CIs. The R software was used for the analyses. Random effects model was carried out with the meta command for pooling data on treatment effect between baseline and first observation after MDA. Generalized linear mixed models were used for the meta-analysis and meta-regression of observations on prevalence rates of schistosomiasis during preventive chemotherapy treatment. To this purpose the lme4 package was used. Data were extracted to get the maximum level of details. In case of available information each data row was an area within a study with a specific treatment for age group. The model contains random intercepts (the study units clustered within studies) and a random slope in time. This means that the rate at which schistosomiasis decline during treatment is different from study-unit to study-unit. If a study-unit has a negative random effect, then they decrease more quickly than the average. Whenever appropriate, we optimized the random effects and the fixed-effects coefficients in the iteratively reweighted least squares step by optimizing the parameter estimation. Wald 95 % confidence intervals (95% CI) were derived. A p-value less than 0.05 was considered as significant in all the analyses.

Heterogeneity assessment

We inspected forest plots for overlapping confidence intervals and outlying data, and where heterogeneity was suspected, we conducted quantitative assessment from the Cochran's Q test and I^2 statistic setting the Chi² test at a more sensitive threshold (P value < 0.1) to indicate statistically significant heterogeneity (DerSimonian and Laird 1986; Bossuyt et al. 2013). The I^2 statistic, defined as the proportion of variation across studies that is due to heterogeneity rather than chance was particularly emphasised, with proportions 0% to 40% reported as less important heterogeneity, 30% to 60% (moderate heterogeneity), 50% to 90% (substantial heterogeneity) and 75% to 100% (considerable heterogeneity). Where significant heterogeneity was detected, we carried out subgroup analyses based on clinical and methodological differences.

Sensitivity analysis

Where data are sufficient, we conducted sensitivity analyses to assess the robustness of the results to the risk of bias components. We used quality dimensions assessed from GRADE and risk of bias assessment to conduct sensitivity analyses by excluding studies considered to be of low quality to explore the robustness of our findings to these factors.

Summary of findings and Grading the evidence

We used GRADE (Alonso-Coello et al 2016) to grade the evidence by looking at 5 main factors that might decrease quality of evidence, 1) study limitations, 2) inconsistency of results, 3) indirectness of evidence, 4) imprecision, and 5) publication bias. We also looked at factors that might increase quality of evidence including, 1) large magnitude of effect, 2) plausible confounding, which would reduce a demonstrated effect, and 3) dose-response gradient (http://www.gradeworkinggroup.org/).

Evidence-to-recommendation

This systematic review and meta-analysis was commissioned by WHO in support of its guideline development for guiding schistosomiasis control in endemic settings. As result, we did evidence-to-recommendation assessment on the following domains: benefits and harms — this required an evaluation of the absolute effects of both benefits and harms (or downsides) of the intervention and their importance where greater net benefit or net harm associated with an intervention or exposure, the greater the likelihood of a strong recommendation in favour or against the

intervention; values and preferences – described the relative importance assigned to health outcomes by those affected by them; how such importance varies within and across populations; and whether this importance or variability is surrounded by uncertainty. The less uncertainty or variability there is about the values and preferences of people experiencing the critical or important outcomes, the greater the likelihood of a strong recommendation; acceptability – the greater the acceptability of an option to all or most stakeholders, the greater the likelihood of a strong recommendation; resource use - pertaining to how resource-intense an intervention was, whether it was costeffective and whether it offered any incremental benefit with the more advantageous or clearly disadvantageous the resource implications were, the greater the likelihood of a strong recommendation either for or against the intervention; equity and human right – the greater the likelihood that the intervention reduced inequities, improved equity or contributed to the realization of one or several human rights as defined under the international legal framework, the greater the likelihood of a strong recommendation; and feasibility – the greater the feasibility of an option from the standpoint of all or most of stakeholders, the greater the likelihood of a strong recommendation considering an overlap of feasibility with values and preferences, resource considerations, existing infrastructures, equity, cultural norms, legal frameworks and many other considerations.

RESULTS

Description of studies

The search retrieved 1,232 studies of which 1186 studies were obtained from electronic databases and 46 studies from other sources including grey literature and contacts with experts. After screening the search returns 1,204 studies were excluded. Fifty-one studies were excluded because of duplication, 1094 studies were not relevant to the topic, 49 studies were excluded because they were either non-MDA, reviews or did not provide treatment. 38 studies met our inclusion criteria but four were excluded from the analysis because they had only baseline data. Of the 34 studies included in the analysis, 15 *S. mansoni* and *S. haematobium*. No study investigated the other schistosome species (Fig. 1). All the MDA campaigns were done in Africa between 1988 and 2020 (Table 1).




Fig. 1 Flowchart of studies retrieved from relevant electronic databases and other sources (including contacts with expert in the field), number meeting the inclusion criteria and number included in the analysis by schistosome species.

Study settings and participants

Of the 34 studies included in the analysis (Table 1), 15 were conducted in West Africa (Sierra Leone = 3, Burkina-Faso = 2, Cote d'Ivoire = 2, Mali = 2, Niger = 2, Senegal = 2, Liberia = 1 and Togo = 1), fourteen studies were conducted in East Africa (Kenya = 8, Tanzania = 3, Uganda = 2) and Ethiopia = 1), 6 studies were conducted in Central and Southern Africa (Burundi = 1, Malawi = 1, Mozambique = 1, Namibia = 1, Rwanda = 1, Zimbabwe = 1) and two studies from North Africa, all conducted in Sudan. Shen et al. (2019) conducted a two-country study in Kenya and Tanzania and reported combined data. Twenty-six studies assessed PZO alone and eight assessed PZQ combined with Albendazole. Twenty-eight studies involved school age children (SAC) and six involved SAC and adults. No MDA has been delivered to adults only. For the detection of the infection, 15 studies that involved people infected with S. mansoni used Kato-Katz (KK), 6 that involved S. haematobium used urine filtration (UF), and 13 studies that involved mixed infection with S. mansoni and S. haematobium employed KK and UF. Only one MDA of S. mansoni infection from Uganda used KK and Circulating Cathodic Antigen (CCA) test. Follow-up time after MDA ranged from 6 months to 9 years (Table 1). Mode of delivery of MDA differed between studies: majority of studies delivered annual PZO MDA least two years, some delivered MDA twice a year (bi-annual) and for some studies, MDA was delivered every two years (biennial). Some studies delivered annual MDA for two years and assessed effect of the treatment after 5 years so that three years elapsed after the last MDA before the outcome of treatment was assessed and some studies alternated MDA with drug holidays.

The majority of data came from SCI or SCORE – supported MDA surveys. SCI provided huge unpublished data and we made sure to avoid duplication of data that has been published from the same data. We did the same with the SCORE data.

	Study ID	Country	Schisto species	Treatment	Population	Diagnosis	Follow-up (months)
1	Abudho et al., 2018	Kenya	Sm	PZQ+ALB	SAC	KK	48
2	Assaré et al., 2016	Cote d'Ivoire	Sm	PZQ	SAC	KK	12
3	Bah et al. 2019	Cote d'Ivoire	Sm + Sh	PZQ	SAC	KK, UF	36
4	Brinkmann et al., 1988	Mali	Sm + Sh	PZQ	SAC	KK, UF	36
5	Bronzan et al., 2015	Togo	Sm + Sh	PZQ+ALB	SAC	KK, UF	72
6	Hamidou et al., 2018	Niger	Sh	PZQ	SAC	UF	60
7	Hodges et al., 2012	Sierra Leone	Sm	PZQ+ALB	SAC	KK	6
8	Karanja et al., 2017	Kenya	Sm	PZQ	SAC	KK	60
9	Knopp et al., 2019	Tanzania	Sh	PZQ	SAC	UF	72
10	Lee et al., 2015	Sudan	Sm + Sh	PZQ	SAC	KK, UF	6-9
11	Moussa et al., 2016	Senegal	Sm + Sh	PZQ	SAC	KK, UF	6
12	Mwandawiro et al., 2019	Kenya	Sm + Sh	PZQ	SAC	KK, UF	60
13	Mwinzi et al., 2012	Kenya	Sm	PZQ+ALB	SAC	KK	6
14	Njenga et al., 2014	Kenya	Sh	PZQ+ALB	SAC	UF	36
15	Olsen et al., 2018	Tanzania	Sm	PZQ	SAC	KK	60
16	Onkanga et al., 2016	Kenya	Sm	PZQ	SAC + Adults	KK	24
17	Ouedraogo et al., 2016	Burkina-Faso	Sh	PZQ+ALB	SAC	UF	108
18	Phillips et al., 2016	Mozambique	Sh	PZQ	SAC	UF	48
19	SCI-supported MDA 1	Burkina Faso	Sm+Sh	PZQ	SAC	KK, UF	48
20	SCI-supported MDA 2	Burundi	Sm	PZQ	SAC + Adults	KK	24
21	SCI-supported MDA 3	Ethiopia	Sm+Sh	PZQ	SAC	KK, UF	72
22	SCI-supported MDA 4	Liberia	Sm+Sh	PZQ	SAC	KK, UF	72
23	SCI-supported MDA 5	Malawi	Sm+Sh	PZQ	SAC	KK, UF	48
24	SCI-supported MDA 6	Mali	Sm+Sh	PZQ	SAC	KK, UF	48
25	SCI-supported MDA 7	Niger	Sm+Sh	PZQ	SAC + Adults	KK, UF	48
26	SCI-supported MDA 8	Rwanda	Sm	PZQ	SAC + Adults	KK	48
27	SCI-supported MDA 9	Tanzania	Sm+Sh	PZQ	SAC + Adults	KK, UF	48-60
28	SCI-supported MDA 10	Uganda	Sm	PZQ	SAC + Adults	KK, CCA	48
29	Zhang et al., 2007	Uganda	Sm	PZQ+ALB	SAC	KK	48
30	Secor et al., 2020	Kenya	Sm	PZQ	SAC	KK	48
31	Senghor et al., 2016	Senegal	Sh	PZQ	SAC	UF	60
32	Sesay et al., 2014	Sierra Leone	Sm	PZQ	SAC	KK	48
33	Shen et al., 2019	Kenya+Tanzania	Sm	PZQ	SAC	KK	36
34	Sircar et al., 2018	Kenya	Sm	PZQ+ALB	SAC	KK	60

Table 1 Characteristics of the studies included in the meta-regression of schistosomiasis MDA

PZQ = Praziquantel; ALB = Albendazole; SAC = School Age Children; Sm =*S. mansoni*; Sh =*S. haematobium*; KK = Kato-Katz; UF = Urine filtration, CCA = Circulating cathodic Antigen. The SCI-supported MDA data came from huge country surveys involving hundreds of villages in 10 Sub-Saharan African countries (Burkina Faso, Burundi, Ethiopia, Liberia, Malawi, Mali, Niger, Rwanda, Tanzania and Uganda). The SCI data were obtained from unpublished records.

Prevalence versus intensity of infection

We estimated the relationship between prevalence and intensity of infection in both *S. mansoni* and *S. haematobium* across different endemicities that showed an inverse quadratic relationship with *S. mansoni* showing slightly steeper curve than *S. haematobium* (Fig. 2). The graphs appear not (fully) in support of the established assumption that prevalence is directly proportional to intensity as a lot of endemic settings with high prevalence do not necessarily have proportionately high intensity (Fig. 2 A and B).




Fig. 2 – Relationship between prevalence (as proportion) and infection intensity of infection expressed as EPG (eggs per gram of faeces) for *S. mansoni* (**A**) or eggs per 10mL of urine for *S. haematobium* (**B**). The data points (black circles) came from 28 large studies involving hundreds of villages and millions of inhabitants for *S. mansoni* and 22 studies of hundreds of villages and thousands of inhabitants treated for *S. haematobium*. Given that egg output does not follow a normal distribution, EPG and eggs/10mL values (x-axis) have been reported on a log scale. A quadratic polynomial regression was fitted to depict the relationship between prevalence and intensity of infection, with their 95% CIs (grey area). The size of the circles is proportional to the size of the population.

Meta-analysis of the effect of MDA over time

We illustrate first the meta-analysis of treatment effect in school age children (SAC) between after baseline and successive follow-up times for S. haematobium infection at 12, 24, 36 and 48 months after annual school-based MDAs (Fig. 3). Eight studies (Phillips et al. 2016; SCI Burkina-Faso; SCI Ethiopia; SCI Liberia; SCI Malawi; SCI Mali; SCI Niger and SCI Tanzania) investigated SAC annual MDA and the results showed statistically significant reduction in the prevalence of infection at 12 months (RR 0.38, 95% CI 0.28 to 0.52; 8 studies, 37,868 school children, I^2 =99%); at 24 months (RR 0.30; 95% CI 0.30 to 0.52; 7 studies; 37107 school children, I^2 =98%); at 36 months (RR 0.39, 95% CI 0.21 to 0.71; 5 studies, 28,146 school children, I^2 =99%)

and at 48 months although this is not statistically significant compared with baseline (RR 0.38, 95% CI 0.14 to 1.07; 2 studies; 10,954 school children, I^2 =98%).

		Follow	Un	Base	ine		Risk Ratio	Risk Ratio
	Study or Subgroup	Events	-	Events		Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1	1.1.1 12months						,,	, , , , , , , , , , , , , , , , , , , ,
	Phillips et al., 2016	644	1290	877	1421	14.0%	0.81 [0.76, 0.87]	•
	SCI Burkina Faso	87	1445	960	1711	13.3%	0.11 [0.09, 0.13]	-
	SCI Ethiopia	2	734	54	1104	3.7%	0.06 [0.01, 0.23]	
	SCI Liberia	344	3713	869	4653	13.8%	0.50 [0.44, 0.56]	• ·
	SCI Malawi	254	4373	510	4853	13.7%	0.55 [0.48, 0.64]	+
	SCI Mali	537	1888	1458	2269	14.0%	0.44 [0.41, 0.48]	•
	SCI Niger	1002	2542	1268	1676	14.0%	0.52 [0.49, 0.55]	•
	SCI Tanzania	157	1843	586	2353	13.6%	0.34 [0.29, 0.40]	+
	Subtotal (95% CI)		17828			100.0%	0.38 [0.28, 0.52]	◆
	Total events	3027		6582				
	Heterogeneity: Tau ² =		² = 485.	75. df = 7	(P < 0.0	0001); i ? :	= 99%	
	Test for overall effect:	•		•		,		
				,				
	1.1.2 24months							
	Phillips et al., 2016	1003	2249	877	1421	13.6%	0.72 [0.68, 0.77]	•
	SCI Burkina Faso	126	1342	960	1711	13.0%	0.17 [0.14, 0.20]	+
	SCI Ethiopia	9	1142	54	1104	7.2%	0.16 [0.08, 0.32]	_
	SCI Liberia	248	2367	869	4653	13.2%	0.56 [0.49, 0.64]	+
	SCI Malawi	206	4221	510	4853	13.1%	0.46 [0.40, 0.54]	+
	SCI Mali	471	1732	1458	2269	13.5%	0.42 [0.39, 0.46]	•
	SCI Niger	976	2635	1268	1676	13.6%	0.49 [0.46, 0.52]	•
	SCI Tanzania	116	1379	586	2353	12.8%	0.34 [0.28, 0.41]	+
	Subtotal (95% CI)		17067		20040	100.0 %	0.39 [0.30, 0.52]	•
	Total events	3155		6582				
	Heterogeneity: Tau ² =	0.14; Ch	= 369.	94, df = 7	(P < 0.0	0001); i ²:	= 98%	
	Test for overall effect:	Z = 6.71 ((P ≤ 0.00	0001)				
	4 4 2 20							
	1.1.3 36months							
	Brinkmann 1988	109	1046	186	760	19.8%	0.43 [0.34, 0.53]	
	Mwandawiro 2019	293	4865	448	4944	20.1%	0.66 [0.58, 0.77]	<u> </u>
	Phillips et al., 2016	1001	2389	877	1421	20.3%	0.68 [0.64, 0.72]	_ •
	SCI Burundi	89	1557	960	1711	19.8%	0.10 [0.08, 0.13]	
	SCI Malawi	206	4600	510	4853	20.0%	0.43 [0.36, 0.50]	÷
	Subtotal (95% CI)		14457		13689	100.0%	0.39 [0.21, 0.71]	-
	Total events	1698		2981	/D			
	Heterogeneity: Tau ² =	-			(P < 0.0	0001); F :	= 99%	
	Test for overall effect:	Z = 3.06 i	(P = 0.00	J2)				
	1.1.4 48months							
	Phillips et al., 2016	891	2346	877	1421	50.8%	0.62 [0.58, 0.66]	
	SCI Malawi	58	2340	510	4853	49.2%	0.24 [0.18, 0.31]	
	Subtotal (95% CI)	00	4680	510		49.2% 100.0%	0.38 [0.14, 1.07]	
	Total events	949	1000	1387	9214		and for the local	
	Heterogeneity: Tau ² =		2- 55 7			001\12-	0.9%	
	Test for overall effect:				0.00	001),1 -	30.0	
	reactor overall effect.	2 - 1.031	, – 0.07	2				
								0.02 0.1 1 10 50
	Test for subaroup diffe	prences.	Chi ^z = 0	01 df= 3	P = 10	ים בייו (חו	%	Favours [Follow Up] Favours [Baseline]
	- rearior auburoup unit		viii – U		A M - 1.0	-0.1 - 0	//	

Test for subgroup differences: $Chi^2 = 0.01$, df = 3 (P = 1.00), $I^2 = 0\%$

Fig. 3 – Forest plot of effectiveness of a single oral dose of 40 mg/kg in SAC for *S. haematobium*. The vertical line at 1 denotes the point of no difference between follow up prevalence and that of baseline so that if the 95% CI includes the value 1, it means there is no statistically significant difference between prevalence at follow up and prevalence at baseline. Each study has a square denoting the 'effect estimate' for that particular study with a horizontal line in the middle of the square that denotes the 95% CI. Each effect size with its CI is presented under 'Risk Ratio'. The size of the square denotes the contribution of the study in the pooled analysis which is quantified by the weight. The narrower the horizontal line (CI) the large the study and the higher our confidence in the estimate. The diamond denotes the pooled (overall) effect estimate.

We assessed the effect of annual MDA in school children (SAC) in a meta-analysis that compared prevalence at baseline with prevalence of *S. mansoni* at follow-up times 12, 24, 36 and 48 months (Fig. 4).

	Follow		Base	line		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight I	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.4.1 12Months							
Abudho et al., 2018	309	897	452	1011	8.4%	0.77 [0.69, 0.86]	-
Assare et al., 2016	598	4667	935	4758	8.4%	0.65 [0.59, 0.72]	•
Onkanga et al., 2016	90	200	126	200	8.0%	0.71 [0.59, 0.86]	+
SCI Burkina Faso	19	322	56	407	5.7%	0.43 [0.26, 0.71]	
SCI Burundi	388	7248	752	7334	8.3%	0.52 [0.46, 0.59]	•
SCI Ethiopia	673	7133	720	10613	8.4%	1.39 [1.26, 1.54]	•
SCI Liberia	566	3835	1201	4653	8.4%	0.57 [0.52, 0.63]	•
SCI Malawi	2	1430	40	1828	1.7%	0.06 [0.02, 0.26]	
SCI Mali	230	1699	557	2043	8.3%	0.50 [0.43, 0.57]	•
BCI Niger	5	1395	14	934	2.8%	0.24 [0.09, 0.66]	
SCI Rwanda	38	2098	193	1500	6.9%	0.14 [0.10, 0.20]	
SCI Tanzania	338	1564	382	1959	8.3%	1.11 [0.97, 1.26]	+
SCI Uganda	1687	6991	2483	7186	8.5%	0.70 [0.66, 0.74]	
Zhang et al., 2007	104	1084	244	1084	7.9%	0.43 [0.34, 0.53]	+
Subtotal (95% CI)	104	40563	244		100.0%	0.56 [0.46, 0.69]	•
Total events	5047		8155			0.000 [0110, 0100]	·
		- 400.14		/0 ~ 0 0	00043-18-1	0704	
Heterogeneity: Tau² = (Fact for overall offect: 7				(F < 0.0	0001),1 = :	97.70	
Test for overall effect: Z	.= 5.50 (F	< 0.000	01)				
1.4.2 24Months							
	225	1000	450	1044	0.400	0.50 (0.54, 0.057)	
Abudho et al., 2018	335	1302	452	1011	8.4%	0.58 [0.51, 0.65]	<u> </u>
Onkanga et al., 2016	68	200	126	200	8.2%	0.54 [0.43, 0.67]	
SCI Burkina Faso	1	146	56	407	2.4%	0.05 [0.01, 0.36]	
SCI Burundi		10993	752	7334	8.4%	0.27 [0.23, 0.30]	•
SCI Ethiopia		10732	720	10613	8.5%	1.39 [1.26, 1.52]	•
SCI Liberia	909	2644	1201	4653	8.5%	1.33 [1.24, 1.43]	•
BCI Malawi	24	1477	40	1828	7.3%	0.74 [0.45, 1.23]	
BCI Mali	161	1586	557	2043	8.4%	0.37 [0.32, 0.44]	+
SCI Niger	8	1454	14	934	5.7%	0.37 [0.15, 0.87]	_
SCI Rwanda	34	2084	193	1500	7.8%	0.13 [0.09, 0.18]	
SCI Tanzania	316	1361	382	1959	8.4%	1.19 [1.04, 1.36]	-
SCI Uganda	1388	7209	2483	7186	8.5%	0.56 [0.53, 0.59]	•
Sircar et al., 2018	0	311	209	386	1.4%	0.00 [0.00, 0.05]	←
Zhang et al., 2007	67	1084	244	1084	8.1%	0.27 [0.21, 0.36]	+
Subtotal (95% CI)		42583		41138	100.0%	0.46 [0.32, 0.66]	◆
Total events	4621		7429				
Heterogeneity: Tau ² = (0.39; Chi ^z	= 1106.3	23, df = 1	3 (P ≤ 0.	00001); I ^z =	99%	
Test for overall effect: Z	. = 4.22 (P	o.000 × ۱	1)				
			.,				
1.4.3 36Months							
Abudho et al., 2018	307	1327	452	1011	18.1%	0.52 [0.46, 0.58]	•
Mwandawiro 2019		21011		21432	17.8%	0.71 [0.62, 0.82]	+
SCI Burkina Faso	12	359	452 56	407	10.0%	0.24 [0.13, 0.45]	
SCI Burundi	104	4053	752	7334	17.1%	0.25 [0.20, 0.31]	+
SCI Malawi	16	4055	40	1828	10.5%	0.41 [0.23, 0.73]	
SCI Malawi SCI Rwanda	7	96	193	1500	8.4%	0.57 [0.27, 1.17]	
	267	96 1612	2483		8.4% 18.1%	0.57 [0.27, 1.17]	
SCI Uganda Subtotal (95% CI)	207	30235	2483	7186 40698	18.1% 100.0%	0.48 [0.43, 0.54]	▲
	1000	30233	4400	10050	100.070	0.00 [0.00, 0.00]	•
Fotal events Listeregeneith: TouZ - (1029	- 77 04	4428	- 0.000	043-17 00-	N/	
Heterogeneity: Tau² = (Test for suprell offest: 7				~ 0.000	01), P = 92'	70	
Test for overall effect: Z	.= 5.78 (P	r < 0.000	U'I)				
1.4.4 48Months							
Abudho et al., 2018	202	1440	452	1011	24.6%	0.31 [0.27, 0.36]	_ •
SCI Burundi	70	3904	752	7334	24.3%	0.17 [0.14, 0.22]	•
SCI Malawi	6	939	40	1828	19.7%	0.29 [0.12, 0.69]	
	918	3220	2483	7186	24.8%	0.83 [0.77, 0.88]	•
	0	235	209	386	6.6%	0.00 [0.00, 0.06]	
SCI Uganda Sircar et al., 2018		9738		17745	100.0%	0.25 [0.11, 0.59]	◆
SCI Uganda							
SCI Uganda Sircar et al., 2018	1196		3936				
SCI Uganda Sircar et al., 2018 Subtotal (95% CI) Total events		= 313.9		P < 0.00	001); i ² = 9!	3%	
SCI Uganda Sircar et al., 2018 Subtotal (95% CI) Fotal events Heterogeneity: Tau ² = (0.73; Chi²), df = 4 (P < 0.00	001); I² = 9!	9%	
SCI Uganda Sircar et al., 2018 S ubtotal (95% CI) Total events Heterogeneity: Tau ² = (0.73; Chi²), df = 4 (P ≺ 0.00	001); I² = 9!	9%	
SCI Uganda Sircar et al., 2018 S ubtotal (95% CI) Total events Heterogeneity: Tau ² = (0.73; Chi²), df = 4 (P < 0.00	001); I² = 9!	9%	
SCI Uganda Sircar et al., 2018 Subtotal (95% CI) Fotal events	0.73; Chi²), df = 4 (P < 0.00	001); I² = 9!	9%	0.001 0.1 1 10 10 Favours [Follow Up] Favours [Baseline]

Fig. 4 Forest plot of effectiveness of single oral dose of 40 mg/kg in SAC for *S. mansoni* (see Fig. 3 for further explanation of the Fig.).

Fourteen studies (Abudho et al. 2016; Assare et al. 2016; Onkanga et al. 2016; SCI Burkina Faso; SCI Burundi; SCI Ethiopia; SCI Liberia; SCI Malawi; SCI Mali; SCI Niger; SCI Rwanda; SCI Tanzania; SCI Uganda and Zhang et al. 2007) investigated SAC annual MDA through schoolbased strategy and the results show a reduction in prevalence with single dose PZQ at 12 months (RR 0.56, 95% CI 0.46 to 0.69; 14 studies, 86,073 school children, I^2 =97%); at 24 months (RR 0.46; 95% CI 0.32 to 0.66; 14 studies; 83,721 school children, I^2 =99%); at 36 months (RR 0.44, 95% CI 0.33 to 0.58; 7 studies, 70933 school children, I^2 =92%) and at 48 months (RR 0.25, 95% CI 0.11 to 0.59; 5 studies; 27,483 school children, I^2 =19%).


Meta-analysis of treatment effect of MDA in adults with *S. mansoni* who received PZQ during School-based treatment by comparing prevalence at baseline and successive follow-up times at 12, 24, 36 and 48 months (Fig. 5).

	Follow	Up	Baseli	ine		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.2.1 12Months							
SCI Burundi	21	222	38	274	21.4%	0.68 [0.41, 1.13]	
SCI Rwanda	7	116	77	187	15.1%	0.15 [0.07, 0.31]	
SCI Tanzania	111	467	278	988	31.0%	0.84 [0.70, 1.02]	•
SCI Uganda	233	680	510	895	32.5%	0.60 [0.53, 0.68]	
Subtotal (95% CI)		1485		2344	100.0%	0.55 [0.38, 0.82]	◆
Total events	372		903	(D	00041		
Heterogeneity: Tau ² =			•	(P < U.	UUU1); F	= 88%	
Test for overall effect	Z = 2.98	(P = 0.0	JU3)				
1.2.2 24Months							
SCI Burundi	6	364	38	274	21.2%	0.12 [0.05, 0.28]	_ _
SCI Rwanda	1	112	77	187	7.3%	0.02 [0.00, 0.15]	
SCI Tanzania	75	514	278	988	35.4%	0.52 [0.41, 0.65]	+
SCI Uganda	105	573	510	895	36.1%	0.32 [0.27, 0.39]	-
Subtotal (95% CI)		1563		2344	100.0%	0.25 [0.14, 0.46]	◆
Total events	187		903				
Heterogeneity: Tau² =				(P ≤ 0.	00001); P	= 89%	
Test for overall effect	Z=4.56	(P < 0.0	00001)				
1.2.3 36Months							
SCI Burundi	4	143	38	274	34.2%	0.20 [0.07, 0.55]	_ _
SCI Rwanda	1	20	77	187	19.6%	0.12 [0.02, 0.83]	
SCI Uganda	28	79	510	895	46.3%	0.62 [0.46, 0.84]	
Subtotal (95% CI)		242		1356	100.0%	0.31 [0.10, 0.93]	-
Total events	33		625				
Heterogeneity: Tau² =	: 0.66; Ch	i² = 7.8	0, df = 2 (P = 0.0	2); I ^z = 74	1%	
Test for overall effect	Z = 2.10	(P = 0.0)4)				
1.2.4 48Months							
SCI Burundi	1	53	38	274	9.9%	0.14 [0.02, 0.97]	
SCI Uqanda	138	591	510	895	90.1%	0.41 [0.35, 0.48]	
Subtotal (95% CI)	100	644	510		100.0%	0.37 [0.19, 0.70]	
Total events	139		548			- / -	•
Heterogeneity: Tau ² =		i ^z = 1.2		P = 0.2	7); I ^z = 19	1%	
Test for overall effect:	•						
		-					
							0.002 0.1 1 10 500
							Favours [Follow Up] Favours [Baseline]
Test for subgroup dif	ferences:	Chi ^z =	5.24, df=	3 (P =	0.15), I ² =	: 42.8%	

Fig. 5 Forest plot of effectiveness of single oral dose of 40 mg/kg in adults with *S. mansoni* through school-based treatment MDA (see Fig. 3 for further explanation of the figure).

Four studies (SCI Burundi; SCI Rwanda; SCI Tanzania and SCI Uganda) investigated SAC annual MDA (Fig. 5). The results demonstrate a similar pattern as *S. haematobium* with MDA showing significant reductions in prevalence at 12 months (RR 0.55, 95% CI 0.38 to 0.46; 4 studies, 3,829 school children, I^2 =88%); at 24 months (RR 0.25; 95% CI 0.14 to 0.46; 4 studies; 3907 school children, I^2 =89%); at 36 months (RR 0.31, 95% CI 0.10 to 0.93; 3 studies, 1598 school children, I^2 =74%) and at 48 months (RR 0.37, 95% CI 0.19 to 0.70; 2 studies; 1,813 school children, I^2 =19%).

The meta-analysis of the effect of MDA in adults that compared baseline and follow-up prevalence of infection after 12, 24, 36 and 48 months of annual Community-Wide Treatment (cwt) has been presented (Fig. 3). Two studies investigated adult cwt MDA and the results showed reduction in the prevalence of infection at 12 months (RR 0.77, 95% CI 0.68 to 0.88; 2 studies, 1,640 school children, moderate heterogeneity I^2 =52%); at 24 months (RR 0.63; 95% CI 0.41 to 0.99; 3 studies; 2,472 school children, very high heterogeneity I^2 =94%); at 36 months (RR 0.40, 95% CI 0.30 to 0.54; 2 studies, 4,628 school children, I^2 =85%)) and at 48 months (RR 0.37, 95% CI 0.19 to 0.70; 2 studies; 1,813 school children, low heterogeneity I^2 =19%)).



Test for subgroup differences: Chi² = 19.66, df = 3 (P = 0.0002), l² = 84.7%

Fig. 5 Forest plot of effect of single oral 40 mg/kg dose in adults with *S. mansoni* treated through cwt MDA campaign (see Fig. 3 for further explanation of the figure).

Longitudinal meta-analysis

Praziquantel showed to be effective in reducing the prevalence of *S. mansoni* (PR=0.83, 95% CI = 0.82 to 0.83) and *S. haematobium* (PR=0.76, 95% CI = 0.75 to 0.76), translating into a 17% annual reduction for *S. mansoni* and 24% annual reduction for *S. haematobium* in PC/MDA programmes (as reported in Table 2 and Fig. 6). There is a sharp drop in prevalence rate after MDA but the decrease becomes less prominent and the curves appear to be leveling off over time. This may have important implications for control as it suggests that prevalence can drop after MDA but at some point it becomes difficult to reduce prevalence further by repeated MDA.

Table 2 - Meta-regression results in terms of Prevalence Ratios (95% CI) per year of treatment*

	Studies	PR (95% CI)	p-value	
S. mansoni	28	0.827 (0.823 to 0.832)	<0.001	
S. haematobium	19	0.756 (0.751 to 0.761)	< 0.001	

*Meta-analyses were performed separately for each species. Estimates are derived from GLLM for longitudinal data.




Fig. 6 Estimated prevalence at baseline and at different follow-up times during annual MDA for *S. mansoni* (A) and *S. haematobium* (B). All the studies used PZQ 40 mg/kg administered as a

single oral dose alone or in combination with Albendazole (400 mg) in MDA campaigns in endemic countries in Sub-Saharan Africa.

We conducted further analysis on prevalence rates at baseline and after annual MDA for SAC and adults for *S. mansoni* and *S. haematobium* (Fig. 7 A, B, C, D). for both SAC and adults prevalence rates decrease, more prominently in SAC (A and C) but not so much for adults with *S. mansoni* or *S. haematobium* (Fig. B and D). Fig. 7B shows that after a decrease of up to 2 years, prevalence starts to increase. The same is observed for MDA for adults with *S. haematobium* where the drop in prevalence levels off after about two years and bounces back (Fig. 7D).




Fig. 7 Prevalence Rates over time points following MDA of adults are plotted for studies that investigated *S. mansoni* in SAC (A), *S. mansoni* in adults (B), *S. haematobium* SAC (C) and S. haematobium adults (D). The size of the circles is proportional to the tested population at each follow-up assessment. Follow up was up to six years.

Longitudinal data

Schisto	N_subjects	N_studies	Com_arms	Age	MDA	Threshold	PR	PR_95_CI
								0.852 (0.833-
S. mansoni	9104	5	5	SAC	Annual CWT	0.05	0.852	0.871)
								0.852 (0.833-
S. mansoni	9104	5	5	SAC	Annual CWT	0.1	0.852	0.871)
								0.852 (0.833-
S. mansoni	9104	5	5	SAC	Annual CWT	0.15	0.852	0.871)
								0.783 (0.775-
S. mansoni	123045	20	181	SAC	Annual SBT	0.05	0.783	0.79)
								0.778 (0.771-
S. mansoni	97943	19	141	SAC	Annual SBT	0.1	0.778	0.786)
								0.769 (0.762-
S. mansoni	84647	18	121	SAC	Annual SBT	0.15	0.769	0.777)
								0.665 (0.63-
S. mansoni	5358	4	32	Adults	Annual SBT	0.05	0.665	0.702)
								0.661 (0.626-
S. mansoni	5065	4	29	Adults	Annual SBT	0.1	0.661	0.698)
								0.66 (0.625-
S. mansoni	4879	4	26	Adults	Annual SBT	0.15	0.66	0.697)
S.								0.821 (0.804-
haematobium	20646	4	4	SAC	Annual CWT	0.05	0.821	0.838)
S.								0.821 (0.804-
haematobium	20646	4	4	SAC	Annual CWT	0.1	0.821	0.838)
S.								0.71 (0.69-
haematobium	13600	3	3	SAC	Annual CWT	0.15	0.71	0.731)
S.								0.743 (0.736-
haematobium	106912	13	123	SAC	Annual SBT	0.05	0.743	0.751)
S.								0.743 (0.736-
haematobium	99931	13	105	SAC	Annual SBT	0.1	0.743	0.751)
S.								0.743 (0.735-
haematobium	91555	13	91	SAC	Annual SBT	0.15	0.743	0.75)
S.								0.575 (0.475-
haematobium	1722	2	6	Adults	Annual SBT	0.05	0.575	0.697)
S.								0.575 (0.475-
haematobium	1722	2	6	Adults	Annual SBT	0.1	0.575	0.697)
S.								0.569 (0.462-
haematobium	1284	2	5	Adults	Annual SBT	0.15	0.569	0.701)

Com_arms = number of communities_arms

Results for specific MDA programs have been described in Table 3 and Table 4. For adults

A	MDA	Baseline	DD (050/ CI)	C4 diag
Age	MDA	Prevalence	PR (95% CI)	Studies
Adults	Annual SBT	low	0.936 (0.716-1.222)	2
Adults	Annual SBT	moderate	0.699 (0.637 to 0.768)	4
Adults	Annual SBT	high	0.659 (0.615 to 0.707)	3
SAC	Annual CWT	high	0.507 (0.457 to 0.562)	3
SAC	Annual SBT	low	0.878 (0.86 to 0.897)	12
SAC	Annual SBT	moderate	0.706 (0.691 to 0.721)	14
SAC	Annual SBT	high	0.682 (0.662 to 0.703)	9
SAC	Annual SBT-CWT	high	0.514 (0.463 to 0.57)	1
SAC	Annual SBT-CWT	moderate	0.678 (0.614 to 0.75)	1

Table 3 - Meta-regression results in terms of Prevalence Ratios (PR, 95% CI) per year of treatment and baseline prevalence or type of treatment for *S. mansoni*

SAC = school age children; CWT = community wide treatment; SBT = school-based treatment; MDA = mass drug administration; PR = prevalence ratio; CI = confident interval. * Estimates are derived from GLLM for longitudinal data.

Table 4 - Meta-regression results in terms of Prevalence Ratios (PR, 95% CI) per year of treatment and baseline intensity of infection or type of treatment for *S. haematobium*

		Baseline		
Age	MDA	Prevalence	PR (95% CI)	Studies
Adults	Annual SBT	moderate	0.585 (0.477 to 0.719)	2
All	Annual CWT	high	0.562 (0.513 to 0.615)	1
All	Annual CWT	moderate	0.471 (0.396 to 0.561)	1
SAC	Annual CWT	high	0.828 (0.811 to 0.845)	3
SAC	Annual SBT	low	0.761 (0.722 to 0.803)	7
SAC	Annual SBT	moderate	0.721 (0.712 to 0.731)	9
SAC	Annual SBT	high	0.774 (0.762 to 0.787)	7
Adults	Annual SBT	moderate	0.585 (0.477 to 0.719)	2

SAC = school age children; cwt = community wide treatment; sbt = school-based treatment; MDA = mass drug administration; PR = prevalence ratio; CI = confident interval. Estimates are derived from GLLM.

Prevalence reduction following MDA

Different communities within a study and repeated follow-ups were each considered as separate data points. The interdependence between observations (communities and repeated follow-ups) within the same study was accounted for by using linear mixed modeling (LMM). In the GLMM study and /or study arms were considered as random intercepts and random slopes (Danso-Appiah and De Vlas 2002). Marginal estimates are then plotted along their 95% CI. The lme4 R package was used to estimate the impact, variance and covariance of random and fixed effects. Significances of the coefficients were assessed by the Wald-test.




Fig. 8 Estimated prevalence at baseline and at different follow-up times during MDA for *S. mansoni* (A-B) and *S. haematobium* (C-D). High prevalence (pink colour) is defined as prevalence \geq 50% by microscopy and \geq 60% by CCA, moderate (blue colour) is prevalence =10% but <50% by microscopy and \leq 15% but <60% by CCA and low prevalence (green colour) is prevalence <10% by and <15% by CCA. All the studies used PZQ 40 mg/kg administered as a single oral dose alone or in combination with Albendazole (400 mg) in MDA campaigns in endemic countries in Sub-Saharan Africa.




Fig. 9a Estimated prevalence at baseline and at different follow-up times during MDA involving school age children for *S. mansoni*. Prevalence categories have been defined using WHO classification (WHO 2012). High prevalence is defined as prevalence \geq 50% by microscopy and \geq 60% by CCA, moderate is prevalence =10% but <50% by microscopy and \leq 15% but <60% by CCA and low prevalence is prevalence <10% by and <15% by CCA. All the studies used PZQ 40 mg/kg administered as a single oral dose alone or in combination with Albendazole (400 mg) in MDA campaigns in endemic countries in Sub-Saharan Africa. SBT means school-based treatment and CWT community wide treatment.

S. mansoni - Adults




Fig. 9b Estimated prevalence at baseline and at different follow-up times during MDA involving Adults for *S. mansoni*. Prevalence categories have been defined using WHO classification (WHO 2012). High prevalence is defined as prevalence \geq 50% by microscopy and \geq 60% by CCA, moderate is prevalence =10% but <50% by microscopy and \leq 15% but <60% by CCA and low prevalence is prevalence <10% by and <15% by CCA. All the studies used PZQ 40 mg/kg administered as a single oral dose alone or in combination with Albendazole (400 mg) in MDA campaigns in endemic countries in Sub-Saharan Africa. SBT means school-based treatment.




Fig. 9c Estimated prevalence at baseline and at different follow-up times during MDA involving school age children for *S. haematobium*. Prevalence categories have been defined using WHO classification (WHO 2012). High prevalence is defined as prevalence \geq 50% by microscopy and \geq 60% by CCA, moderate is prevalence =10% but <50% by microscopy and \leq 15% but <60% by CCA and low prevalence is prevalence <10% by and <15% by CCA. All the studies used PZQ 40 mg/kg administered as a single oral dose alone or in combination with Albendazole (400 mg) in MDA campaigns in endemic countries in Sub-Saharan Africa. SBT means school-based treatment and CWT community wide treatment.

S. haematobium - Adults




Fig. 9d Estimated prevalence at baseline and at different follow-up times during MDA involving Adults for *S. haematobium*. Prevalence categories have been defined using WHO classification (WHO 2012). High prevalence is defined as prevalence \geq 50% by microscopy and \geq 60% by CCA, moderate is prevalence =10% but <50% by microscopy and \leq 15% but <60% by CCA and low prevalence is prevalence <10% by and <15% by CCA. All the studies used PZQ 40 mg/kg administered as a single oral dose alone or in combination with Albendazole (400 mg) in MDA campaigns in endemic countries in Sub-Saharan Africa. SBT means school-based treatment.




Fig. 10a Estimated prevalence at baseline and at different follow-up times during MDA involving school age children for *S. mansoni*. All the studies used PZQ 40 mg/kg administered as a single oral dose alone or in combination with Albendazole (400 mg) in MDA campaigns in endemic countries in Sub-Saharan Africa.

S. mansoni - Adults




Fig. 10b Estimated prevalence at baseline and at different follow-up times during MDA involving adults for *S. mansoni*. All the studies used PZQ 40 mg/kg administered as a single oral dose alone or in combination with Albendazole (400 mg) in MDA campaigns in endemic countries in Sub-Saharan Africa.




Fig. 10c Estimated prevalence at baseline and at different follow-up times during MDA involving school age children for *S. haematobium*. All the studies used PZQ 40 mg/kg administered as a single oral dose alone or in combination with Albendazole (400 mg) in MDA campaigns in endemic countries in Sub-Saharan Africa.

S. haematobium - Adults




Fig. 10d Estimated prevalence at baseline and at different follow-up times during MDA involving Adults for *S. haematobium*. All the studies used PZQ 40 mg/kg administered as a single oral dose alone or in combination with Albendazole (400 mg) in MDA campaigns in endemic countries in Sub-Saharan Africa.




Fig 12a Expected prevalence rates reduction in SAC MDAs for *S. mansoni* according to longitudinal analyses. Different lines represent different thresholds. SBT stands for School Based Treatment and CWT for Community Wide Treatment.




Fig. 12b Expected prevalence rates in SAC MDAs for *S. haematobium* according to longitudinal analyses. Different lines represent different thresholds. SBT stands for School Based Treatment and CWT for Community Wide Treatment.

Risk of Bias Assessment

The risk of bias in the included studies has been represented graphically (Fig. 13). Thirty-four studies were assessed to be of low Risk of Bias due to confounding and selection of participants into the study, bias in classification of interventions bias due to deviations from intended interventions and bias in selection of reported results. For Bias in measurement of outcomes, all the studies were considered to have moderate bias whilst only three studies had information on missing data and scoring moderate; the rest did not report on missing data. None of the studies had high risk of bias, all were assessed to have moderate risk (Table 7).

Of the 34 studies included in the meta-analysis, all of them had low risk of bias due to confounding, low risk of bias due in selection of participants, low risk of bias in the classification of intervention, low risk of bias due to due to deviations from intended interventions and low risk of bias in selective reporting of outcomes. All the 34 studies showed moderate risk of bias in measurement of outcomes. None of the studies had serious or critical risk of bias in them (Table 7).




Figure 13 Graphical representation of Risk of bias in the included studies in the systematic review

Study	Bias due to confounding	Bias in selection of participants	Bias in classification of interventions	Bias due to deviations from intended interventions	Bias due to missing data	Bias in measurement of outcomes	Bias in selection of reported results	OVERALI BIAS Modera
Abudho et al., 2018	Low	Low	Low	Low	NI*	Moderate	Low	Modera
Assare et al., 2016	Low	Low	Low	Low	Moderate	Moderate	Low	Modera
Bah et al., 2019	Low	Low	Low	Low	NI	Moderate	Low	Modera
Brinkmann et al., 1988	Low	Low	Low	Low	NI	Moderate	Low	Modera
Bronzan et al., 2015	Low	Low	Low	Low	Moderate	Moderate	Low	Modera
Hamidou et al., 2018	Low	Low	Low	Low	NI	Moderate	Low	Modera
Hodges et al., 2012	Low	Low	Low	Low	NI	Moderate	Low	Modera
Karanja et al., 2017	Low	Low	Low	Low	NI	Moderate	Low	Modera
Knopp et al., 2019	Low	Low	Low	Low	NI	Moderate	Low	Modera
Lee et al., 2015	Low	Low	Low	Low	NI	Moderate	Low	Modera
Moussa et al., 2016	Low	Low	Low	Low	NI	Moderate	Low	Modera
Mwandawiro et al., 2019	Low	Low	Low	Low	NI	Moderate	Low	Modera
Mwinzi et al., 2012	Low	Low	Low	Low	NI	Moderate	Low	Modera
Njenga et al.,2014	Low	Low	Low	Low	NI	Moderate	Low	Modera
Olsen et al., 2018	Low	Low	Low	Low	NI	Moderate	Low	Modera
Onkanga et al., 2016	Low	Low	Low	Low	NI	Moderate	Low	Modera Modera
Ouedraogo et al., 2016	Low	Low	Low	Low	NI	Moderate	Low	
Phillips et al., 2017	Low	Low	Low	Low	Moderate	Moderate	Low	Modera

Table 7 Results of risk of bias assessment of the studies included in the systematic review

SCI-supported MDA 1	Low	Low	Low	Low	NI	Moderate	Low	Moderate
SCI-supported MDA 2	Low	Low	Low	Low	NI	Moderate	Low	Moderate
SCI-supported MDA 3	Low	Low	Low	Low	NI	Moderate	Low	Moderate
SCI-supported MDA 4	Low	Low	Low	Low	NI	Moderate	Low	Moderate
SCI-supported MDA 5	Low	Low	Low	Low	NI	Moderate	Low	Moderate
SCI-supported MDA 6	Low	Low	Low	Low	NI	Moderate	Low	Moderate
SCI-supported MDA 7	Low	Low	Low	Low	NI	Moderate	Low	Moderate 7
SCI-supported MDA 8	Low	Low	Low	Low	NI	Moderate	Low	Moderate e com made Moderate e com as to com
SCI-supported MDA 9	Low	Low	Low	Low	NI	Moderate	Low	Modera
SCI-supported MDA 10	Low	Low	Low	Low	NI	Moderate	Low	Modera
Secor et al., 2020	Low	Low	Low	Low	NI	Moderate	Low	Moderate
Senghor et al., 2016	Low	Low	Low	Low	NI	Moderate	Low	Moderate
Sesay et al., 2014	Low	Low	Low	Low	NI	Moderate	Low	Modera
Shen et al., 2019	Low	Low	Low	Low	NI	Moderate	Low	Moderate medRing Moderate medRing Moderate
Sircar et al. 2018	Low	Low	Low	Low	NI	Moderate	Low	Modera
Zhang et al., 2007	Low	Low	Low	Low	NI	Moderate	Low	Modera
Low	34	34	34	34	0	0	34	Moderate of a visit and spreprint in perpetuity. 0 34 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Moderate	0	0	0	0	3	34	О	34 av
Serious	0	0	0	0	0	0	О	o pr
Critical	0	0	0	0	0	0	0	order in o
* No information (NI)	0	0	0	0	31	0	0	
. ,					~			etuity.
				34				F

SUMMARY OF FINDINGS

PICOS

Population
• Whole population or subgroups (Pre-SAC, SAC, adults including pregnant and lactating women) infected with any of the schistosome species or non-infected, living in endemic areas who received PZQ during a PC or MDA programme
Intervention
• Praziquantel at a single oral dose 40 mg/kg and above or in combination with Albendazole, Mebendazole, Pyrantel pamoate or Levamisole (for soil-transmitted helminthiasis), or Albendazole plus either Ivermectin or Diethylcarbamazine [DEC] (for lymphatic filariasis), ACTs (for malaria), or Azithromycin (Zithromax) for trachoma.
Comparators
• WHO recommended prevalence thresholds (for low, moderate and high endemicities)
Outcomes
Primary outcomes
 Post MDA prevalence of infection or percent reduction at follow-up Post MDA intensity of infection or percent reduction of egg count at follow-up Post MDA transmission or percent reduction in transmission at follow-up

Secondary outcomes

- Compliance and acceptance of the intervention by the population
- Cost effectiveness of the prevalence threshold selected for PC
- Cost effectiveness of the diagnostic criteria selected for PC

Benefits and harms (adverse events)

LEVEL OF EVIDENCE (GRADE)

	Anticipated absolute effects* (95% CI)										
Outcomes	Without preventive chemotherapy	With preventive chemotherapy	Relative effect (95% CI)	Number of participant s (studies)	Quality of the evidence (GRADE)	Comments					
One-year prevalence reduction of <i>S. mansoni</i> in SAC (Annual SBT; 0 to 1 year)	8,155/45,510 (17.9%)	5,047/40,563 (12.4%)	PR = 0.56 (0.46 to 0.69)	45,510 (14)	⊕⊕⊕⊙	NA					
4 years prevalence reduction of <i>S. mansoni</i> in SAC (Annual SBT; 0 to 4 year)	3,936/17,745 (22.2%)	1,196 /9,738 (12.3%)	PR = 0.25 (0.11 to 0.59)	17,745 (5)	⊕⊕⊕⊙	NA					
Annual prevalence reduction of <i>S. mansoni</i> in SAC (Annual SBT; Threshold >5%; follow-up: range 1-7 years)	-	-	PR = 0.78 (0.77 to 0.79)	123,045 (20)	⊕⊕⊕⊙	NA					
One-year prevalence reduction of <i>S. haematobium</i> in SAC (Annual SBT; 0 to 1 year)	6,582/20,040 (32.8%)	3,027/17,828 (17.0%)	PR = 0.38 (0.28 to 0.52)	20,040 (8)	⊕⊕⊕⊙	NA					
4 years prevalence reduction of <i>S. haematobium</i> in SAC (Annual SBT; 0 to 4 years)	1,387/6,274 (22.1%)	949/4,680 (20.3%)	PR = 0.38 (0.28 to 0.52)	6,724 (2)	⊕⊕⊙⊙	NA					
Annual prevalence reduction of <i>S. haematobium</i> in SAC (Annual SBT; Threshold >5%; follow-up: range 1-7 years)	-	-	PR = 0.74 (0.73 to 0.75)	106,912 (13)	⊕⊕⊕⊙	NA					

GRADE Working Group grades of evidence (Guyatt et al., 2013)

 $\oplus \oplus \oplus \oplus$ High quality: We are very confident that the true effect lies close to that of the estimate of effect.

 $\oplus \oplus \oplus \odot$ Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

$\oplus \oplus \odot \odot$ Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
$\oplus \odot \odot \odot \odot$ Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.

Discussion

This systematic review and meta-analysis showed the relationship between prevalence and intensity of infection is not linear, instead quadratic polynomial relationship. Obviously, this has implications for policy and control. The pooled data come from thousands of communities that representing the diversity of demography, settings and schistosome dynamics and, therefore, informative. Also, given that assumed linear relationship held by many may not be accurate means that caution should be exercised when justifying the use of prevalence as a proxy for determining the threshold upon which to justify an MDA. We suggest more rigorous work that attempts to conduct head-to-head comparison of prevalence and intensity is warranted to ascertain which of the two measures is more stable and responsive across settings and contexts to measure effect of MDA.

The results also showed that when given as annual MDA, prevalence of *S. mansoni* and *S. haematobium* in school age children decreases, but no apparent difference between baseline and 48 months. Similarly, annual MDA for *S. mansoni* achieved a reduction for SAC and adults but no apparent further reduction after 12 months by repeated MDA. Community-wide treatment sowed similar results. Annual mass drug administration for up to 9 years did not achieve prevalence reduction to the elimination target for *S. mansoni* in settings with baseline prevalence $\geq 10\%$. For *S. haematobium*, although annual mass drug administration up to 5 years reduced prevalence to lower levels than *S. mansoni*, elimination target was not reached in setting with baseline prevalence $\geq 10\%$ by 10 years of mass drug administration will be required to achieve elimination when baseline prevalence is $\geq 10\%$. Further analyses using a series of prevalence thresholds showed no apparent difference in the time to elimination between 5% and 10%, 15%, 20%, 30% and 40%, but higher than 10% thresholds took longer to achieve elimination.

as a lot of endemic settings with high prevalence, as pooled in this analysis, do not necessarily appear to support that. This means that to have an appropriate threshold to justify MDA, we need to reassess both prevalence and intensity and find which one is more stable to use as threshold for population MDA.

Heterogeneity between the studies pooled was high ($I^2 > 97\%$) but given the huge number of studies and individuals treated, this is not likely to influence the study conclusions. This could be a possible explanation of 'real' differences between MDA programmes which is what the I^2 is measuring. In terms of strategy, some MDA programmes treated only SAC (sbt), SAC and occupationally at-risk adults (SAC and adults) or community wide treatment (cwt). In some settings, other control measures that took place during the same period of the MDA, villages differed in baseline intensity of infection and thereby force of transmission, variation in sensitivities in diagnostic criteria existed between MDA programmes as well as differences in follow-up times after MDA. As data on some of these factors were not documented or in formats

that could be used, these variations could not be quantitatively addressed in the meta-analysis or sub-group analysis.

Heterogeneity between the studies pooled in this meta-analysis was high ($I^2 > 95\%$ in most of the analysis) but given the huge number of studies and individuals treated, between studies heterogeneity is not expected to change the direction of treatment effect or the overall conclusions from this review. The high levels of heterogeneity could be explained by the following: 1) there are 'real' differences between MDA programmes so the I^2 values are a true reflection, 2) MDA programmes differed in strategy (some treated only SAC, SAC and occupationally at risk adults (SAC and adults) or community wide treatment, 3) other control measures took place during the period of the MDA in some cases but not accounted for in reporting the results of MDAs, 4) villages differed in baseline intensity of infection and thereby force of transmission, 5) variation in sensitivities in diagnostic criteria existed between MDA programmes, and 6) differences existed in follow-up times of MDAs.

Data on some of these factors were not documented or presented in formats that could be used in this systematic review and meta-analysis and therefore some of these variations could not be quantitatively addressed in the meta-analysis or in sub-group analyses.

Conclusions and recommendations

The evidence presented in this review (given ethical implications) suggests that 10% prevalence can be used as the 'global' prevalence threshold for MDA in endemic countries.

- Most of data are from SAC population, no data on pre-school children and few on adults makes is difficult to make concrete statement about generazability of the review findings
- From this review, PZQ appears to be effective in reducing the prevalence of schistosomiasis at 12 months, but incremental benefit of repeated annual treatment appears to be minimal in further reducing prevalence over time
- In both light prevalence and intensity, infection rates do not decrease but rather tended to increase with biennial MDA
- Effectiveness depends of several factors, which are difficult to disentangle, however the rate of prevalence decrease seems not influenced by the baseline intensity of infection and type of treatment
- Further analyses were conducted from a series of created prevalence thresholds of 5%, 10%, 15%, 20%, 30% and ≥40% and although showed differences in effect of MDA, the differences in effect based on threshold regressed over time (after about 8 years). For annual MDA of SAC, SBT appears to perform better than CWT in terms of prevalence reduction. For schistosome species, the model suggests, using the same prevalence threshold, it will take shorter time to reach elimination for *S. haematobium* than *S. mansoni*; annual MDA for *S. haematobium* (SBT) will require about 10 years to achieve elimination whereas it will take longer for *S. mansoni* (over 10 years to around 15 years to achieve elimination).

- The question that remains is what happens to endemic communities/settings with less than 10% prevalence?
- Integration of non-pharmacological interventions such access to water, improved sanitation, hygiene education (WASH) and snail control will complement MDA to achieve elimination of schistosomiasis

REFERENCES

INCLUDED STUDIES

- Abudho BO, Ndombi EM, Guya B, Carter JM, Riner DK, Kittur N, Karanja DMS, Secor WE, Colley DG. Impact of Four Years of Annual Mass Drug Administration on Prevalence and Intensity of Schistosomiasis among Primary and High School Children in Western Kenya: A Repeated Cross-Sectional Study. Am. J. Trop. Med. Hyg., 98(5), 2018, 1397– 1402
- Assaré RK, Tian-Bi YN, Yao PK, N'Guessan NA, Ouattara M, Yapi A, Coulibaly JT, Meïté A, Hürlimann E, Knopp S, Utzinger J, N'Goran EK. Sustaining Control of Schistosomiasis Mansoni in Western Côte d'Ivoire: Results from a SCORE Study, One Year after Initial Praziquantel Administration. PLoS Negl Trop Dis. 2016 Jan 20;10(1):e0004329. doi: 10.1371/journal.pntd.0004329. eCollection 2016 Jan.
- Bronzan RN, Dorkenoo AM, Agbo YM, Halatoko W, Layibo Y, Adjeloh P, et al. Impact of community-based integrated mass drug administration on schistosomiasis and soiltransmitted helminth prevalence in Togo. PLoS Negl Trop Dis 2018,12(8): e0006551. https://doi.org/10.1371/journal.pntd.0006551
- Karanja DMS, Awino EK, Wiegand RE, Okoth E, Abudho BO, Mwinzi PNM, Montgomery SP, Secor WE. Cluster randomized trial comparing school-based mass drug administration schedules in areas of western Kenya with moderate initial prevalence of *Schistosoma mansoni* infections. PLoS Negl Trop Dis 2017; 11(10): e0006033. <u>https://doi.org/10.1371/journal.pntd.0006033</u>
- Ouedraogo H, Drabo F, Zongo D, Bagayan M, Bamba I, Pima T, Yago-Wienne F, Toubali E, Zhang Y. Schistosomiasis in school-age children in Burkina Faso after a decade of preventive chemotherapy. Bull World Health Organ. 2016 Jan 1;94(1):37-45. doi: 10.2471/BLT.15.161885. Epub 2015 Nov 24.
- Schutte CHJ, Evans AC, Pammenter MD, Cooppan RM, Pretorius SJ, Joubert PH. Epidemiology and control of schistosomiasis mansoni in communities living on the Cuondo River Floodplains of East Caprivi, Namibia. Annals of Tropical Medicine, 1995; vol 89, 6:631-644
- Sesay S, Paye J, Bah MS, McCarthy FM, Conteh A, Sonnie M, Hodges MH, Zhang Y. Schistosoma mansoni infection after three years of mass drug administration in Sierra Leone. Parasit Vectors. 2014 Jan 9;7:14. doi: 10.1186/1756-3305-7-14.
- Onkanga IO, Mwinzi PN, Muchiri G, Andiego K, Omedo M, Karanja DM, Wiegand RE, Secor WE, Montgomery SP. Impact of two rounds of praziquantel mass drug administration on Schistosoma mansoni infection prevalence and intensity: a comparison between community wide treatment and school based treatment in western Kenya. Int J Parasitol. 2016 Jun;46(7):439-45. doi: 10.1016/j.ijpara.2016.01.006. Epub 2016 Mar 2.
- Wiegand RE, Mwinzi PNM, Montgomery SP, Chan YL, Andiego K, Omedo M, Muchiri G, Ogutu MO, Rawago F, Odiere MR, Karanja DMS, Secor WE. A Persistent Hotspot of Schistosoma mansoni Infection in a Five-Year Randomized Trial of Praziquantel Preventative Chemotherapy Strategies. J Infect Dis. 2017 Dec 12;216(11):1425-1433. doi: 10.1093/infdis/jix496.
- Zhang Y1, Koukounari A, Kabatereine N, Fleming F, Kazibwe F, Tukahebwa E, Stothard JR, Webster JP, Fenwick A. Parasitological impact of 2-year preventive chemotherapy on schistosomiasis and soil-transmitted helminthiasis in Uganda. BMC Med. 2007 Sep 3;5:27.

- Hodges MH, Dada N, Warmsley A, Paye J, Bangura MM, Nyorkor E, Sonnie M, Zhang Y. Mass drug administration significantly reduces infection of *Schistosoma mansoni* and hookworm in school children in the national control program in Sierra Leone. BMC Infectious Diseases 2012, 12:16, <u>http://www.biomedcentral.com/1471-2334/12/16</u>
- Phillips AE, Gazzinelli-Guimaraes PH, Aurelio HO, Ferro J, Nala R, Clements M, King CH, Fenwick A, Fleming FM, Dhanani N. Assessing the benefits of five years of different approaches to treatment of urogenital schistosomiasis: A SCORE project in Northern Mozambique. PLoS Negl Trop Dis. 2017 Dec 8;11(12):e0006061. doi: 10.1371/journal.pntd.0006061. eCollection 2017 Dec.
- Hamidou AA, Tohon Z, Sofo B, Dhanani NA, Gnandou I, Sidikou B, Noma AG, Madougou B, Alto O, Sebangou H, Kader M, Andia HR, Garba A, Fenwick A, Phillips AE. Evaluating the impact of biannual treatment on urogenital schistosomiasis in Niger. Report, Unpublished
- Garba A, Barkiré N, Djibo A, Lamine MS, Sofo B, Gouvras AN, Bosqué-Oliva E, Webster JP, Stothard JR, Utzinger J, Fenwick A. Schistosomiasis in infants and preschool-aged children: Infection in a single Schistosoma haematobium and a mixed S. haematobium-S. mansoni foci of Niger. Acta Trop. 2010 Sep;115(3):212-9. doi: 10.1016/j.actatropica.2010.03.005. Epub 2010 Mar 19.
- Senghor B, Diaw OT, Doucoure S, Seye M, Diallo A, Talla I, Bâ CT, Sokhna C. Impact of Annual Praziquantel Treatment on Urogenital Schistosomiasis in a Seasonal Transmission Focus in Central Senegal. PLoS Negl Trop Dis. 2016 Mar 25;10(3):e0004557. doi: 10.1371/journal.pntd.0004557. eCollection 2016 Mar.
- Njenga SM, Mutungi FM, Wamae CN, Mwanje MT, Njiru KK, Bockarie MJ. Once a year school-based deworming with praziquantel and albendazole combination may not be adequate for control of urogenital schistosomiasis and hookworm infection in Matuga District, Kwale County, Kenya, Report, Unpublished
- Mwinzi PN, Montgomery SP, Owaga CO, Mwanje M, Muok EM, Ayisi JG, Laserson KF, Muchiri EM, Secor WE, Karanja DM.Integrated community-directed intervention for schistosomiasis and soil transmitted helminths in western Kenya - a pilot study. Parasit Vectors. 2012 Aug 31;5:182.
- Mwinzi PN, Muchiri G, Wiegand RE, Omedo M, Abudho B, Karanja DM, Montgomery SP, Secor WE. Predictive Value of School-Aged Children's Schistosomiasis Prevalence and Egg Intensity for Other Age Groups in Western Kenya. Am J Trop Med Hyg. 2015 Dec;93(6):1311-7. doi: 10.4269/ajtmh.15-0467. Epub 2015 Sep 28.
- Ortu G, Khan J, Samuel Yibi M, Abdu Nimaya I. Mass drug administration in Central Equatoria, South Sudan: results and suggestions for future distributions. Int Health. 2017 Jul 1;9(4):263-266. doi: 10.1093/inthealth/ihx025.
- Sircar AD, Mwinzi PNM, Onkanga IO, Wiegand RE, Montgomery SP, Secor WE1.Schistosoma mansoni Mass Drug Administration Regimens and Their Effect on Morbidity among Schoolchildren over a 5-Year Period-Kenya, 2010-2015. Am J Trop Med Hyg. 2018 Aug;99(2):362-369. doi: 10.4269/ajtmh.18-0067. Epub 2018 Jun 7.

- Kheir MM, Baraka OZ, El-Tom IA, Mukhtar MM, Homeida MMA. Effects of single-dose praziquantel on morbidity and mortality resulting from intestinal schistosomiasis. Eastern Mediterranean Health Journal, 2000; vol 6, 5-6:927-931
- Kittur N, Binder S, Campbell CH, King CH, Kinung'hi S, Olsen A, Magnussen P, Colley DG. Defining Persistent Hotspots: Areas That Fail to Decrease Meaningfully in Prevalence after Multiple Years of Mass Drug Administration with Praziquantel for Control of Schistosomiasis. Am J Trop Med Hyg. 2017 Dec;97(6):1810-1817. doi: 10.4269/ajtmh.17-0368. Epub 2017 Sep 21.
- Landouré A, Dembélé R, Goita S, Kané M, Tuinsma M, Sacko M, Toubali E, French MD, Keita AD, Fenwick A, Traoré MS, Zhang Y. Significantly reduced intensity of infection but persistent prevalence of schistosomiasis in a highly endemic region in Mali after repeated treatment. PLoS Negl Trop Dis. 2012;6(7):e1774. doi: 10.1371/journal.pntd.0001774. Epub 2012 Jul 31.
- Lee YH, Jeong HG, Kong WH, Lee SH, Cho HI, Nam HS, Ismail HA, Alla GN, Oh CH, Hong ST. Reduction of urogenital schistosomiasis with an integrated control project in Sudan. PLoS Negl Trop Dis. 2015 Jan 8;9(1):e3423. doi: 10.1371/journal.pntd.0003423. eCollection 2015 Jan.
- Midzi N, Mtapuri-Zinyowera S, Sangweme D, Paul NH, Makware G, Mapingure MP, Brouwer KC, Mudzori J, Hlerema G, Chadukura V, Mutapi F, Kumar N, Mduluza T. Efficacy of integrated school based de-worming and prompt malaria treatment on helminths -Plasmodium falciparum co-infections: A 33 months follow up study. BMC Int Health Hum Rights. 2011 Jun 22;11:9. doi: 10.1186/1472-698X-11-9.
- Moussa A, Babacar F, Darnycka BMR, Clément TR, Oumar G. Effectiveness of Semestrial Mass Administration of Praziquantel 600 mg in the Schistosomiasis High Transmission Areas of Senegal River Basin. International Journal of TROPICAL DISEASE & Health 17(3): 1-7, 2016, Article no.IJTDH.27007 ISSN: 2278–1005, NLM ID: 101632866, SCIENCEDOMAIN international: www.sciencedomain.org

OTHER REFERENCES

- Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Rada G, Rosenbaum S, Morelli A, Guyatt GH, Oxman AD; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016 Jun 28;353:i2016. doi: 10.1136/bmj.i2016. No abstract available.
- A, Colley DG, Fleming FM, Haggag Bärenbold O. Garba AA, Ramzy EM, Mbonigaba RMR, Assaré RK, Tukahebwa JB, Bucumi V, Kebede B, JT. N'Goran Yibi MS, Meité A. Coulibaly EK, Tchuem Tchuenté L-A, Mwinzi P, Utzinger J, Vounatsou P. Translating preventive chemotherapy prevalence thresholds for Schistosoma mansoni from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test. PLoS Negl Trop Dis, 2018 Dec 14;12(12):e0006941, doi: 10.1371/journal.pntd.0006941. eCollection 2018 Dec.
- Bossuyt P, Davenport C, Deeks J, Hyde C, Leeflang M, Scholten R. Chapter 11: Interpreting results and drawing conclusions. In: Deeks JJ, Bossuyt PM, Gatsonis C, editors. Cochrane

handbook for systematic reviews of diagnostic test accuracy, Version 0.9. Oxford: The Cochrane Collaboration; 2013. Available from: http://methods.cochrane.org/sdt/sites/methods.cochrane.org.sdt/files/uploads/DTA%20Ha ndbook%20Chapter%2011%20201312.pdf

- Danso-Appiah A, Minton J, Boamah D, Otchere J, Asmah RH, Rodgers M, Bosompem KM, Eusebi P, De Vlas SJ. Accuracy of point-of-care testing for circulatory cathodic antigen in the detection of schistosome infection: systematic review and meta-analysis. Bull World Health Organ. 2016 Jul 1;94(7):522-533A. doi: 10.2471/BLT.15.158741. Epub 2016 Apr
- Danso-Appiah A, De Vlas SJ. Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. rends Parasitol. 2002 Mar;18(3):125-9. doi: 10.1016/s1471-4922(01)02209-7.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986. September;7(3):177–88. 10.1016/0197-2456(86)90046-2
- Eusebi P, Reitsma JB, Vermunt JK. Latent class bivariate model for the meta-analysis of diagnostic test accuracy studies. BMC Med Res Methodol. 2014;14(1):88. 10.1186/1471-2288-14-88.
- Fenwick A, Rollinson D, Southgate V (2006) Implementation of human schistosomiasis control: challenges and prospects. Adv Parasitol 61:567–622.
- Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming FM et al (2009) The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002–2008.
- Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochranehandbook.org, 2011.
- Hotez PJ. Mass drug administration and integrated control for the world's high-prevalence neglected tropical diseases. Clin Pharmacol Ther 2009; 85:659–664.
- Hotez P Enlarging the "Audacious Goal": elimination of the world's high prevalence neglected tropical diseases. Vaccine 2011; 29(Suppl 4):D104–D110. doi:10.1016/j.vaccine.2011.06.024.
- Hoy D, Brooks P, Woolf A, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012;65:934–9.
- King CH, et al. 2020, Impact of different mass drug administration strategies for gaining and sustaining control of Schistosoma mansoni and Schistosoma haematobium infection. Am J Trop Med Hyg 103 (Suppl 1): 14-23.
- Linehan M, Hanson C, Weaver A, Baker M, Kabore A et al (2011) Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: proving the feasibility at national scale. Am J Trop Med Hyg 84(1):5–14
- Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed.1000097.
- Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi: 10.1136/bmj.i4919.
- Uniting to Combat NTDs 2012. London Declaration on neglected tropical diseases. http://unitingtocombatntds.org/resource/london-declaration.

- Vermunt JK, Magidson J. Technical guide for latent GOLD 5.0: basic, advanced, and syntax. Belmont: Statistical Innovations Inc.; 2013. Available from: http://www.statisticalinnovations.com/latent-gold-5-1/.
- Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med 2007;45:247–51.
- WHO. Schistosomiasis: Progress Report 2001-2011 and Strategic Plan 2012-2020. 2012a.
- WHO. Accelerating work to overcome the global impact of neglected tropical disease: a road map for implementation. 2012b. WHO/HTM/NTD/2012, 37 pp.
- WHO. Prevention and control of schistosomiasis and soil-transmitted helminthiasis: A Report of WHO Expert Committee. 2006 (WHO Technical Report Series 912) Geneva, P 1-57.
- WHO. The control of schistosomiasis: Second report of the WHO Expert Committee (WHO technical report series; 912), 2002. Geneva, P 1-94.
- WHO. Report of the WHO Informal Consultation on Schistosomiasis Control. Geneva 2-4 December, 1998;1-44.
- WHO. The Control of Schistosomiasis. Second report of the WHO Expert Committee 1993. Technical Report Series No. 830. Geneva.
- WHO. The Control of Schistosomiasis: Report of WHO Expert Committee. Technical Report
SeriesNo.1985;728.Geneva.

APPENDIX 1

Evidence-to-recommendation table

ΡΙϹΟ

Population

• Whole population or subgroups (Pre-SAC, SAC, adults including pregnant and lactating women) infected with any of the schistosome species or non-infected and living in endemic areas who received PZQ during a PC or any MDA programme

Intervention

• Praziquantel at a single oral dose (50, 60, 70 or 80 mg/kg or in combination with Albendazole, Mebendazole, Pyrantel pamoate or Levamisole (for soil-transmitted helminthiasis), or Albendazole plus either Ivermectin or Diethylcarbamazine [DEC] (for lymphatic filariasis), ACTs (for malaria), or Azithromycin (Zithromax) for trachoma.

Comparators

• WHO recommended prevalence thresholds for low, moderate and high endemicities

Outcomes

Primary outcomes

- Post MDA prevalence of infection or percent reduction at well-defined follow-up times
- Post MDA intensity of infection or percent reduction of egg count at well-defined follow-up times
- Post MDA transmission or percent reduction in transmission at well-defined follow-up times

Secondary outcomes

- Compliance and acceptance of the intervention by the population.
- Cost effectiveness of the prevalence threshold selected for PC.
- Cost effectiveness of the diagnostic criteria selected for PC.

Benefits and harms (adverse events)

Evidence-to-recommendation tables

	Description of the factor to consider	Criteria	Judgements	Evidence	Additional information (by GDG members)
Benefits and harms	This requires an evaluation of the absolute effects of both benefits and harms (or downsides) of the intervention and their importance. The greater the net benefit or net harm associated with an intervention or exposure, the greater the likelihood of a strong recommendation in favour or against the intervention.	Do the desirable effects outweigh the undesirable effects?	⊠ Yes □ No □ Uncertain	The current systematic review showed high benefit of PZQ at a single dose of 40 mg/kg in terms of prevalence and intensity of infection from schistosomiasis PC/MDA. Other high-quality systematic reviews $(1, 2, 3, 4)$ and randomised controlled trials $(5, 6)$ have shown similar results. Systematic review assessing adverse events associated with PZQ reported mild to moderate adverse and transient events. None reported serious events $(1, 2, 3, 4)$.	•
Values and Preferences	This describes the relative importance assigned to health outcomes by those affected by them; how such importance varies within and across populations; and whether this importance or variability is surrounded by uncertainty. The less uncertainty or variability there is about the values and preferences of people experiencing the critical or important outcomes, the greater the likelihood of a strong recommendation.	Is there important uncertainty or variability about how much people value the options?	 ☐ Major uncertainty or variability ⊠ Minor uncertainty or variability ☐ Unknown 	Recent reviews showed that in several communities there are some concerns on risk of adverse events and also lack of trust in information. (1,2) However, studies reporting MDA showed a high treatment coverage, in general above the recommended percentage of WHO.	•

Acceptability	The greater the acceptability of an option to all or most stakeholders, the greater the likelihood of a strong recommendation.	Is the option acceptable to key stakeholders?	⊠ Yes □ No □ Uncertain	 PZQ can be administered in several formulations for complete acceptability by treated people, including schoolaged children. In fact, it is available also in crushed tablet form and mixed with orange-juice (3). Previous studies have shown that the fruit flavour helped to mask the bitter taste of PZQ (4) and acceptability is high (5) Optimal community participation remains challenging, but several studies identified key factors for reaching the target as education, community workers training, praziquantel tasting, timing not interfering with agricultural activities, trust in care information and careful consideration of prior adverse events (1,2,6–8) 	,
Resource use	This pertains to how resource-intense an intervention is, whether it is cost– effective and whether it offers any incremental benefit. The more advantageous or clearly disadvantageous the resource implications are, the greater the likelihood of a strong recommendation either for or against the intervention.	How large are the resource requirements?	☐ Major resources ⊠ Minor resources ☐ Uncertain	Cost-effectiveness of PZQ MDA is proven by several studies (3,9–11). In one observation treatment costs were estimated at US\$0.74 for school-aged children and \$1.74 for preschool-aged children and adults (10) while in another study were US\$0.54 for school-aged-children (12). In these as in other studies MDA was judge as cost-effective. The estimated cost from WHO for a single 600-mg tablet is about US\$ 0.08 and an average treatment is estimated to be between US\$ 0.20–0.30. Praziquantel is now available free of charge to high-disease burden countries in sub-Saharan Africa, through a donation from Merck Serono to the WHO.	Þ
Equity and Human rights	The greater the likelihood that the intervention will reduce inequities, improve equity or contribute to the realization of one or several human rights as defined under the international legal framework, the greater the likelihood of a strong recommendation.	What would be the impact on health equity?	 ☐ Increased equity ☐ Reduced equity ☐ Uncertain 	The recommendation of scaling-up MDA will end-up with an increased equity in term of access to healthcare and averted life years spent with disability and reduced mortality. Schistosomiasis does primarily affect low and middle-income countries, and reducing the disease burden would improve equity.	•
Feasibility	The greater the feasibility of an option from the standpoint of all or most of stakeholders, the greater the likelihood of a strong recommendation. Feasibility overlaps with values and preferences, resource considerations, existing infrastructures, equity, cultural norms, legal frameworks and many other considerations.	Is the option feasible to implement?	⊠ Yes □ No □ Uncertain	• The intervention is feasible, as shown by the large number of studies in the field and the conduct of MDA program according to the previous WHO guidelines.	Þ

Decision table

Balance of Consequences	 Undesirable consequences clearly outweigh desirable consequences Undesirable consequences probably outweigh desirable consequences The balance between desirable and undesirable consequences is closely balanced or uncertain Desirable consequences probably outweigh undesirable consequences Desirable consequences clearly outweigh undesirable consequences in most settings 		
Type of Recommendation	The strength of a recommendation expresses the degree to which the GDG is confident in the balance between the desirable and undesirable consequences of implementing the recommendation. When a GDG is very certain about this balance (i.e. the desirable consequences clearly outweigh the undesirable consequences), it issues a strong recommendation in favour of an intervention. When it is uncertain about this balance, however, it issues a conditional (or "weak") recommendation . Policy-makers:Strong recommendationConditional recommendation		 Strong recommendation for Conditional recommendation for Only in specific context Strong recommendation against Conditional recommendation against No recommendation can be made because evidence of the effectiveness or harm of was not identified.

	The recommendation can be adopted as policy in most situations.	Policy-making will require substantial debate and involvement of various stakeholders.	
--	---	---	--

Recommendation	Recommended.
Remarks	More data from low, moderate and high endemicity settings are needed to update the evidence. Need to strengthen the key factors for treatment compliance such as education, training of personnel program and increase of adequate information to communities.

References- evidence to recommendations

- 1. Krentel A, Fischer PU, Weil GJ. A Review of Factors That Influence Individual Compliance with Mass Drug Administration for Elimination of Lymphatic Filariasis. PLoS Negl Trop Dis. 2013;
- 2. Shuford K V., Turner HC, Anderson RM. Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: A systematic review. Parasites and Vectors. 2016.
- 3. WHO. Preventive chemotherapy in human helminthiasis: a manual for health professionals and programme managers. Use of Anthelminthic Drugs in Control. 2006.
- 4. Korenromp EL, Arnold F, Williams BG, Nahlen BL, Snow RW. Monitoring trends in under-5 mortality rates through national birth history surveys. Int J Epidemiol. 2004;
- 5. Namwanje H, Kabatereine NB, Olsen A. The acceptability and safety of praziquantel alone and in combination with mebendazole in the treatment of Schistosoma mansoni and soil-transmitted helminthiasis in children aged 1-4 years in Uganda. Parasitology. 2011;
- 6. Katsivo MN, Muthami LN, Kimani S, Karama M, Kingori F. Involvement of a community in schistosomiasis control: a Kenyan experience. East Afr Med J. 1993;
- 7. Knopp S, Person B, Ame SM, Ali SM, Muhsin J, Juma S, et al. Praziquantel coverage in schools and communities targeted for the elimination of urogenital schistosomiasis in Zanzibar: A cross-sectional survey. Parasites and Vectors. 2016;
- 8. Chami GF, Kontoleon AA, Bulte E, Fenwick A, Kabatereine NB, Tukahebwa EM, et al. Profiling Nonrecipients of Mass Drug Administration for Schistosomiasis and Hookworm Infections: A Comprehensive Analysis of Praziquantel and Albendazole Coverage in Community-Directed Treatment in Uganda. Clin Infect Dis. 2016;
- 9. Lo NC, Lai YS, Karagiannis-Voules DA, Bogoch II, Coulibaly JT, Bendavid E, et al. Assessment of global guidelines for preventive chemotherapy against schistosomiasis and soil-transmitted helminthiasis: a cost-effectiveness modelling study. Lancet Infect Dis. 2016;
- Lo NC, Bogoch II, Blackburn BG, Raso G, N'Goran EK, Coulibaly JT, et al. Comparison of community-wide, integrated mass drug administration strategies for schistosomiasis and soiltransmitted helminthiasis: A cost-effectiveness modelling study. Lancet Glob Heal. 2015;3(10):e629– 38.
- 11. Cioli D, Pica-Mattoccia L, Basso A, Guidi A. Schistosomiasis control: Praziquantel forever? Molecular and Biochemical Parasitology. 2014.
- 12. Brooker S, Kabatereine NB, Fleming F, Devlin N. Cost and cost-effectiveness of nationwide schoolbased helminth control in Uganda: Intra-country variation and effects of scaling-up. Health Policy Plan. 2008;